CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region

Journal of Neurochemistry

Volumn 106, Issue 3, 2008, Pages 1092-1103

  Moriguchi, Shigeki ^a   Shioda, Norifumi ^a   Han, Feng ^a   Narahashi, Toshio ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Calcium calmodulin dependent protein kinase II; Long term potentiation; N methyl D aspartate acid; Nefiracetam; Protein kinase C

Indexed keywords

AMPA RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEFIRACETAM; NICOTINIC RECEPTOR; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE C ALPHA; SYNAPTOPHYSIN;

ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HIPPOCAMPUS; IMMUNOBLOTTING; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; PROTEIN KINASE C; PYRROLIDINONES; RATS; RATS, WISTAR;

RATTUS;

EID: 48249090845     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05440.x     Document Type: Article

References (47)

1. Barria A., Muller D., Derkach V., Griffith L. C. Soderling T. R. (1997) Regulatory phosphorylation of AMPA-type glutamate receptor by CaM-KII during long-term potentiation. Science 276, 2042 2045.
2. Baxter M. G., Lanthorn T. H., Frink K. M., Golski S., Wan R. Olton D. S. (1994) d-Cycloserine, a novel cognitive enhancer, improves spatial memory in aged rats. Neurobiol. Aging 15, 207 213.
3. Bliss T. V. Collingridge G. L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31 39.
4. 2+/calmodulin- kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionate type glutamate receptors. Proc. Natl Acad. Sci. USA 96, 3269 3274.
5. Dysken M. W., Mendels J. LeWitt P. (1992) Milacemide; a placebo-controlled study in senile dementia of the Alzheimer type. Am. J. Geriatr. Psychiatry 40, 503 506.
6. Edwards S., Simmons D. L., Galindo D. G., Doherty J. M., Scott A. M., Hughes P. D. Wilcox R. E. (2002) Antagonistic effects of dopaminergic signaling and ethanol on protein kinase A-mediated phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor. Alcoholism 26, 173 180.
7. Fley U., Huang Y. Y. Kandel E. R. (1993) Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 260, 1661 1664.
8. Fukunaga K. Miyamoto E. (2000) A working model of CaM Kinase II activity in hippocampal long-term potentiation and memory. Neurosci. Res. 38, 3 17.
9. 2+/calmodulin-dependent protein kinase II in rat brain and various tissues. J. Neurochem. 51, 1070 1078.
10. 2+/calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J. Biol. Chem. 267, 22527 22533.
11. 2+/ calmodulin-dependent protein kinase II. J. Biol. Chem. 268, 7863 7867.
12. 2+/calmodulin-dependent protein kinase II and its endogenous substrates in the induction of long term potentiation. J. Biol. Chem. 270, 6119 6124.
13. Giacobini E. (2000) Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer's disease. Alzheimer Dis. Assoc. Disorders 14 (Suppl. 1 S3 S10.
14. 3H]glutamate binding. J. Neurochem. 48, 543 551.
15. Hanndelmann G. E., Nevins M. E., Mueller L. L., Arnolde S. M. Cordi A. A. (1989) Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic reodents. Pharmacol. Biochem. Behav. 34, 823 828.
16. Kamphuis W., Hendriksen E. Lopes da Silva F. H. (1995) Isozyme specific changes in the expression of protein kinase C isozyme (alpha-zeta) genes in the hippocampus of rats induced by kindling epileptogenesis. Brain Res. 702, 94 100.
17. Laemmli U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680 685.
18. Lisman J., Schulman H. Cline H. (2002) The molecular basis of CaMKII function in synaptic and behavioral memory. Nat. Rev. Neurosci. 3, 175 190.
19. 2+/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation. J. Neurosci. 19, 8292 8299.
20. Lledo P. M., Hjelmstad G. O., Mukherji S., Soderling T. R., Malenka R. C. Nicoll R. A. (1995) Calcium/calmodulin-dependent kinase II and long-term potentiation enhance synaptic transmission by the same mechanism. Proc. Natl Acad. Sci. USA 92, 11175 11179.
21. Lovinger D. M., Wong K. L., Murakami K. Routtenberg A. (1987) Protein kinase C inhibitors eliminate hippocampal long-term potentiation. Brain Res. 436, 177 183.
22. Lynch G., Kessler M., Arai A. Larson J. (1990) The nature and causes of hippocampal long-term potentiation. Prog. Brain Res. 83, 233 250.
23. Maelicke A. Albuquerque E. X. (2000) Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol. 393, 165 170.
24. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig L., Albuquerque E. X. Zerlin M. (2001) Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49, 279 288.
25. Malenka R. C. Nicoll R. A. (1999) Long-term potentiation - a decade of progress? Science 285, 1870 1874.
26. Mammen A. L., Kameyama K., Roche K. W. Huganir R. L. (1997) Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J. Biol. Chem. 272, 32528 32533.
27. Moriguchi S., Marszalec W., Zhao X., Yeh J. Z. Narahashi T. (2003) Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J. Pharmacol. Exp. Ther. 307, 160 167.
28. Moriguchi S., Marszalec W., Zhao X., Yeh J. Z. Narahashi T. (2004) Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J. Pharmacol. Exp. Ther. 310, 933 942.
29. Moriguchi S., Shioda N., Maejima H., Zhao X., Marszalec W., Yeh J. Z., Fukunaga K. Narahashi T. (2007) Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Mol. Pharmacol. 71, 580 587.
30. Nabeshima T. (1994) Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction. Drugs Today 30, 357 379.
31. Nabeshima T., Nakayama S., Ichihara K., Yamada K., Shiotani T. Hasegawa T. (1994) Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task. Eur. J. Pharmacol. 255, 57 65.
32. Nishizaki T., Matsuoka T., Nomura T., Matsuyama S., Watabe S., Shiotani T. Yoshii M. (1999) A 'long-term-potentiation-like' facilitation of hippocampal synaptic transmission induced by the nootropic nefiracetam. Brain Res. 826, 281 288.
33. Ohmitsu M., Fukunaga K., Yamamoto H. Miyamoto E. (1999) Phosphorylation of myristoylated alanine-rich protein kinase C substrate by mitogen-activated protein kinase in cultured rat hippocampal neurons following stimulation of glutamate receptors. J. Biol. Chem. 274, 408 417.
34. Roche K. W., O'Brien R. J., Mammen A. L., Bernhardt J. Huganir R. L. (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16, 1179 1188.
35. Santos M. D., Alkondon M., Pereira E. F., Aracava Y., Eisenberg H. M., Maelicke A. Albuquerque E. X. (2002) The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 61, 1222 1234.
36. Schrattenholz A., Pereira E. F. R., Roth U., Weber K. H., Albuquerque E. X. Maelicke A. (1996) Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49, 1 6.
37. Schwartz B. L., Hashtroudi S., Herting R. L., Handerson H. deutch S. I. (1991) Glycine prodrug facilitates momory retrieval in humans. Neurology 41, 1341 1343.
38. Schwartz B. L., Hashtroudi S., Herting R. L., Schwartz P. deutsch S. I. (1996) d-Cycloserine enhances implicit memory in Alzheimer's patients. Neurology 46, 420 424.
39. Sieber F. E., Traystman R. J., Brown P. R. Martin L. J. (1998) Protein kinase C expression and activity after global incomplete cerebral ischemia in dogs. Stroke 29, 1445 1452.
40. Soderling T. R. Derkach V. A. (2000) Postsynaptic protein phosphorylation and LTP. Trends Neurosci. 23, 75 80.
41. Tingley W. G., Roche K. W., Thompson A. K. Huganir R. L. (1993) Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364, 70 73.
42. Tingley W. G., Ehlers M. D., Kameyama K., Doherty C., Ptak J. B., Riley C. T. Huganir R. L. (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272, 5157 5166.
43. Vanhoose A. M. Winder D. G. (2003) NMDA and beta-1 adrenergic receptors differently signal phosphorylation of glutamate receptor type 1 in area CA1 of hippocampus. J. Neurosci. 23, 5827 5834.
44. Wafford K. A., Kathoria M., Bain C. J., Marshall G., Le Bourdelles B., Kemp J. A. Whiting P. J. (1995) Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol. Pharmacol. 47, 374 380.
45. Yamagata Y. (2003) New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J. Pharmacol. Sci. 93, 22 29.
46. Yoshii M., Watabe S., Sakurai T. Shiotani T. (1997) Cellular mechanism of underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav. Brain Res. 83, 185 188.
47. Zhao X., Kuryatov A., Lindstorm J. M., Yeh J. Z. Narahashi T. (2001) Nootropic drug modulation of neuronal nicotinic acethylcholine receptors in rat cortical neurons. Mol. Pharmacol. 59, 674 683.